Skip to content
glp1.here

How to get GLP-1 care

Guide

Who typically qualifies for a GLP-1 medicine

By the glp1.here editorial team. Published November 18, 2026. Last reviewed November 18, 2026.

“Do I qualify?” is a clinical question wearing a search query. Labels describe populations studied and populations the FDA approved a drug for. They do not enroll you. A prescriber still has to decide that the indication fits, that a contraindication does not, and that the likely benefit is worth the labeled risks for the person in front of them. This page quotes those population rules. It does not screen you. The prescription guide is about the visit where that decision is made. The tirzepatide monograph restates Zepbound’s dose schedule once a prescriber has already chosen that drug.

Body mass index is the label’s measuring stick, not a verdict

The NHLBI calculator defines BMI as weight relative to height and sorts adult results into underweight, healthy weight, overweight, and obesity. Labels for chronic weight management use that scale. They do not all use it in the same sentence, and several products now have indications that are not “weight loss” at all.

For Wegovy injection, the weight-reduction indication covers adults and adolescents 12 and older with obesity, and adults with overweight plus at least one weight-related comorbid condition, together with diet and activity. The label does not print a single BMI numeral in the indication sentence the way older summaries sometimes did. In the clinical-trial descriptions, obesity is identified with BMI of 30 kg/m² or greater and overweight with BMI in the range the study used, often 27 to 29.9 kg/m² with a comorbidity. STEP 1, the 68-week trial of semaglutide 2.4 mg, enrolled adults with BMI of 30 or greater, or 27 or greater with at least one weight-related condition, and without diabetes. Mean weight change was −14.9 percent with semaglutide and −2.4 percent with placebo. That enrollment rule is not a promise that everyone with the same BMI should receive the drug. It is who was studied.

Zepbound’s weight-reduction indication is for adults with obesity or adults with overweight and at least one weight-related comorbid condition. SURMOUNT-1 enrolled adults with BMI of 30 or more, or 27 or more with at least one weight-related complication, excluding diabetes. Mean weight change at 72 weeks was −15.0 percent, −19.5 percent, and −20.9 percent with tirzepatide 5 mg, 10 mg, and 15 mg, versus −3.1 percent with placebo. Again, those are trial populations and trial averages.

Saxenda’s indication names adults and pediatric patients 12 and older with body weight greater than 60 kg and obesity, and adults with overweight plus at least one weight-related comorbid condition. The pediatric weight floor is easy to miss if a page only talks about BMI.

Indications that are not the weight-loss indication

Qualifying for a drug can mean qualifying for a different line on the same label.

Wegovy is also indicated to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. It is indicated, under accelerated approval, for noncirrhotic MASH with moderate to advanced fibrosis. Those uses have their own evidence sections. A person can fit one and not another.

Zepbound is indicated to treat moderate to severe obstructive sleep apnea in adults with obesity. The maintenance doses the label recommends for that use are 10 mg or 15 mg weekly, which is narrower than the weight-reduction maintenance options of 5 mg, 10 mg, or 15 mg.

Ozempic injection, a different semaglutide product, is indicated for glycemic control in adults with type 2 diabetes, for major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. It is not the weight-management label. People sometimes use the word “Ozempic” when they mean any GLP-1 drug. The indications are not interchangeable. NIDDK’s table makes the brand-and-use distinction in patient language: Wegovy for weight, Ozempic and Rybelsus as the diabetes names and doses of semaglutide.

If your goal is a diabetes indication, a cardiovascular indication, sleep apnea, or MASH, say that to the clinician. The paperwork a plan requires often follows the indication, which is why the prior authorization sheet starts by asking what the prescription is actually for.

Histories that push the other way

Contraindications are not “use with caution” lines. Wegovy is contraindicated with a personal or family history of medullary thyroid carcinoma, with MEN 2, and with a prior serious hypersensitivity to semaglutide or to any excipient in the product being used. Zepbound and Saxenda carry the same thyroid contraindication pattern. A family story of “thyroid cancer” needs a specific diagnosis, because the most common thyroid cancers are not medullary thyroid carcinoma. The clinician, not a webpage, has to sort that.

Pregnancy is a stop-and-plan situation rather than, on the current Wegovy highlights, a formal contraindication heading. The warning is still strong: the drug may cause fetal harm, and for weight reduction or cardiovascular risk reduction it should be discontinued when pregnancy is recognized and at least two months before a planned pregnancy. Zepbound’s label says to discontinue when pregnancy is recognized. Breastfeeding recommendations differ by product. Wegovy tablets, for example, are in a “breastfeeding not recommended” line on the highlights. Read the label of the product in your hand.

Other warnings should be in the visit even though they are not absolute contraindications: history of pancreatitis, gallbladder disease, severe gastrointestinal disease, diabetic retinopathy in people with type 2 diabetes, and kidney disease that could worsen if vomiting causes dehydration. Scheduled surgery matters because labels now warn about pulmonary aspiration during anesthesia or deep sedation in people on GLP-1 drugs, which slow gastric emptying. Tell the surgical team. Do not decide on your own to stop or continue. That instruction should come from the clinicians involved.

Children are not small adults in these labels. Wegovy injection has a pediatric obesity indication from age 12. Wegovy tablets, as described in the adult dosing section for weight reduction, are an adult presentation. Zepbound’s weight and sleep-apnea indications are for adults. Mounjaro, the diabetes tirzepatide product, has a pediatric diabetes indication that is a different monograph. If the patient is under 18, the product name matters even more.

What “typically” does not mean

Typically, adults whose BMI is in the obesity range, or in the overweight range with a condition such as hypertension, dyslipidemia, or obstructive sleep apnea, are the people clinicians evaluate for the weight-management indications. Typically, the visit also looks for the thyroid history, pregnancy plans, and drug interactions above. Typically is not the same as automatically. STEP 1 excluded diabetes. SURMOUNT-1 excluded diabetes. People with diabetes were studied in other trials, at different doses and with different average weight change. A clinic that quotes only the largest percentage on a billboard is not quoting the label’s full story.

Two more limits are practical. First, labels say not to combine GLP-1 receptor agonists. Already taking one is a reason to switch under supervision, not to add a second. Second, a program’s internal rules can be stricter than the label. A plan or a clinic may require a higher BMI, a documented lifestyle attempt, or a sleep study. Those rules are coverage or practice policy. They are not FDA indications. Ask which document a denial is citing.

Approved and unapproved products matter after the qualification question, because qualifying for a medicine is not the same as qualifying for a compounded copy. Cost and the first weeks matters because a person can meet a label and still be unable to fill the prescription at a price they can pay. Neither fact changes the medical criteria. It changes what you do with a yes.

Sources

  1. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s041lbl.pdf
  3. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/206321s024lbl.pdf
  4. https://www.nhlbi.nih.gov/calculate-your-bmi
  5. https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
  6. https://pubmed.ncbi.nlm.nih.gov/33567185/
  7. https://pubmed.ncbi.nlm.nih.gov/35658024/
  8. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42bdd912-2393-44c4-b7e0-47672ca28991